Triple-negative breast cancer: The impact of guideline-adherent adjuvant treatment on survival-a retrospective multi-centre cohort study

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 1073-1080

  Schwentner, L ^a   Wolters, R ^b   Koretz, K ^a   Wischnewsky, M B ^b   Kreienberg, R ^a   Rottscholl, R ^a   Wockel A ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

Breast cancer; Guideline; Survival; Triple negative

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; ETHNIC GROUP; EVIDENCE BASED MEDICINE; FEMALE; GERMAN; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GUIDELINE ADHERENCE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84865200479     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1935-y     Document Type: Article

References (18)

1. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR et al (2011) Basallike and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157-167
2. Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41(1):40-47
3. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25-32
4. Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(1):1-11
5. Teng YH, Thike AA, Wong NS, Tan PH (2011) Therapeutic targets in triple negative breast cancer: where are we now? Recent Pat Anticancer Drug Discov 6(2):196-209
6. Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3):627-636
7. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138-140
8. Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, Wischnewsky MB, Wöckel A (2011) A comparison of international breast cancer guidelines: do the national guidelines differ in treatment recommendations? Eur J Cancer doi:10.1016/j.ejca.2011.06.020
9. Kreienberg R, Kopp I, Lorenz W, Budach W, Dunst J, Lebeau A et al. (2004) Guidelines for diagnosis and treatment for breast cancer in women. National Cancer Society 2004
10. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. N Engl J Med 363(20):1938-1948
11. Chacon RD, Costanzo MV (2010) Triple negative breast cancer. Breast Cancer Res 12(2):S3
12. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683-692
13. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE et al (2008) Get with guidelines: stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119(1):107-115
14. Wöckel A, Kurzeder C, Geyer V, Novopashenny I, Wolters R, Wischnewsky M et al (2010) Effects of guideline adherence in primary breast cancer: a 5 year multi-center cohort study of 3976 patients. Breast 19:120-127
15. Hamaker ME, Schreurs WH, Uppelschoten JM, Smorenburg CH (2009) Breast cancer in the elderly: retrospective study on diagnosis and treatment according to national guidelines. Breast J 15:26-33
16. Varga D, Wischnewsky M, Atassi Z, Wolters R, Geyer V, Strunz K, Kreienberg R, Woeckel A (2010) Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology 78(3-4):189-195
17. Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D, Blettner M, Kreienberg R (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748-753
18. Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodal negative breast cancer. J Clinical Oncol 22:3685-3693